A Milestone for Keratoconus Treatment
Glaukos Corporation has announced a significant regulatory and reimbursement milestone for its innovative therapy, Epioxa™ (Epioxa HD / Epioxa), designed to treat Keratoconus—a progressive and potentially sight-threatening corneal condition. The Centers for Medicare and Medicaid Services (CMS) has officially assigned a permanent Healthcare Common Procedure Coding System (HCPCS) J-code—J2789—to Epioxa. This new code is scheduled to take effect on July 1, 2026, marking an important step toward improving patient access, reimbursement clarity, and broader adoption of the therapy.
This development is expected to play a crucial role in facilitating the commercial rollout of Epioxa across the United States by simplifying billing procedures and enhancing payer confidence in covering the treatment.
Understanding J-Codes and Their Importance
J-codes are a subset of HCPCS Level II codes used by healthcare providers in the United States to report injectable drugs and certain biologics administered in clinical settings. These codes are essential for ensuring accurate billing and reimbursement from both government programs like Medicare and private insurance providers.
The assignment of a unique J-code, such as J2789 for Epioxa, allows for:
- Standardized identification of the therapy across healthcare systems
- Streamlined claims processing
- Greater transparency in reimbursement
- Reduced administrative burden for providers
Without a dedicated J-code, providers often rely on miscellaneous or temporary codes, which can lead to delays, inconsistencies, and reimbursement challenges. Therefore, the issuance of a permanent, product-specific J-code is widely considered a critical milestone for any new therapeutic entering the U.S. market.
Epioxa: A Novel Approach to Keratoconus Care
Keratoconus is a progressive eye disease characterized by thinning and bulging of the cornea into a cone-like shape, leading to distorted vision and, in severe cases, vision loss. Despite its seriousness, the condition is frequently underdiagnosed and undertreated, partly due to limited awareness and access to advanced treatment options.
Epioxa introduces a transformative approach to managing keratoconus. Unlike traditional corneal cross-linking procedures, which typically require removal of the corneal epithelium (the outermost layer of the eye), Epioxa offers a non-invasive, incision-free alternative.
Key features of Epioxa include:
- Epithelium-on procedure: Eliminates the need for epithelial removal, reducing discomfort
- Oxygen-enriched formulation: Enhances the effectiveness of the treatment
- UV light activation: Enables targeted bioactivation for corneal strengthening
- Minimized recovery time: Allows patients to return to normal activities more quickly
This innovative design aims to improve patient experience while maintaining or enhancing clinical outcomes.
Clinical and Patient Benefits
The advantages of Epioxa extend beyond procedural convenience. By eliminating the need to remove the corneal epithelium, the therapy addresses one of the most significant pain points associated with traditional cross-linking procedures—post-operative pain and extended recovery periods.
Patients undergoing conventional treatments often experience:
- Significant discomfort during recovery
- Increased risk of infection
- Temporary vision impairment
- Longer healing times
Epioxa seeks to mitigate these challenges by offering a gentler, more patient-friendly approach. The reduced invasiveness not only enhances patient comfort but may also encourage earlier intervention, which is critical in slowing the progression of keratoconus.
Strategic Implications for Market Access
According to Glaukos leadership, the assignment of J-code J2789 is a pivotal step in advancing the company’s market access strategy. The new code is expected to improve reimbursement consistency and reduce uncertainty for both providers and payers.
Thomas Burns, Chairman and CEO of Glaukos, emphasized that this milestone supports efforts to expand coverage and increase accessibility for patients. With a dedicated J-code in place, healthcare providers can more confidently adopt Epioxa into their treatment offerings, knowing that billing and reimbursement pathways are clearly defined.
This development is particularly important in the context of rare diseases like keratoconus, where treatment adoption can be hindered by reimbursement complexities and limited payer awareness.
Enhancing Healthcare System Efficiency
The introduction of J2789 is also expected to benefit the broader healthcare ecosystem. By simplifying administrative processes and reducing billing ambiguities, the new code can contribute to:
- Faster claims approvals
- Lower administrative costs
- Improved provider workflow efficiency
- Greater alignment between clinical and financial systems
For payers, the ability to accurately track and reimburse for Epioxa treatments may lead to more consistent coverage policies and better cost management.
Supporting Commercial Launch and Growth
The timing of the J-code’s effectiveness—July 1, 2026—aligns strategically with Glaukos’ plans for the commercial launch of Epioxa. Having reimbursement infrastructure in place at launch is critical for ensuring rapid uptake and minimizing barriers to adoption.
The company anticipates that the new code will:
- Strengthen the foundation for commercialization
- Accelerate provider adoption
- Expand patient access nationwide
- Support long-term revenue growth
As healthcare providers become more familiar with Epioxa and its benefits, the presence of a permanent J-code will likely play a key role in driving utilization.
Addressing an Unmet Medical Need
Despite advances in ophthalmology, keratoconus remains a condition with significant unmet needs. Many patients are diagnosed late, and treatment options have historically been limited or invasive.
Epioxa’s innovative approach, combined with improved reimbursement support, has the potential to shift the treatment paradigm by:
- Encouraging earlier diagnosis and intervention
- Reducing barriers to care
- Improving patient outcomes
- Increasing awareness among healthcare providers
By addressing both clinical and systemic challenges, Epioxa may help close the gap between diagnosis and effective treatment.
Looking Ahead: Broader Impact and Future Potential
The assignment of J-code J2789 represents more than just a reimbursement update—it signals growing recognition of Epioxa’s value within the healthcare system. As adoption increases, the therapy could set a new standard for keratoconus treatment, particularly in terms of patient comfort and procedural efficiency.
Looking forward, continued collaboration between Glaukos, healthcare providers, and payers will be essential to fully realize the benefits of this innovation. Ongoing education, clinical data generation, and real-world evidence will further support the integration of Epioxa into routine care.
The CMS assignment of a permanent J-code (J2789) for Epioxa marks a significant milestone in the evolution of keratoconus treatment. By enabling streamlined billing and reimbursement, the new code is expected to enhance access, support commercial success, and ultimately improve outcomes for patients living with this challenging condition.
With its non-invasive design, patient-centric benefits, and strong reimbursement foundation, Epioxa stands poised to make a meaningful impact in ophthalmic care—offering new hope to those affected by keratoconus and setting the stage for broader innovation in the field.
About Glaukos
Glaukos is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rare corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.
Dosage and Administration: EPIOXA HD and EPIOXA are for topical ophthalmic use. NOT for injection or intraocular use. EPIOXA HD and EPIOXA are supplied in single-dose syringes. Discard opened syringes after use. EPIOXA HD and EPIOXA are for use with the O2n System and Boost Goggles only. Refer to the O2n System Operator’s Manual and Boost Goggles User Guide for device instructions.
Contraindications: EPIOXA HD and EPIOXA are contraindicated in patients with known hypersensitivity to benzalkonium chloride or any ingredients in EPIOXA HD and EPIOXA. Epithelium-on corneal collagen cross-linking is contraindicated in aphakic and pseudophakic patients without a UV-blocking intraocular lens.
Warnings and Precautions: Corneal collagen cross-linking should be used with caution in patients with a history of herpetic keratitis due to the potential for reactivation of herpes keratitis.
Adverse Reactions:The most common adverse reaction was conjunctival hyperaemia (31%). Other adverse reactions, occurring in 5% to 25% of eyes included: corneal opacity (haze), photophobia, punctate keratitis, eye pain, eye irritation, increased lacrimation, corneal epithelium defect, eyelid oedema, corneal striae, visual acuity reduced, dry eye, and anterior chamber flare.
